Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus Surgery
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 6, 2025 -- A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to a study published online Jan. 29 in Clinical and Translational Allergy.
Sanna Toppila-Salmi, from University of Eastern Finland in Kuopio, and colleagues investigated predictors of revision ESS at one and three years in 3,506 patients with CRSwNP.
The researchers found that 15.9 percent of the patients had at least one revision surgery during the follow-up, with a median time to revision of ESS of 425 days. Higher odds of revision ESS were seen with baseline asthma (odds ratio [OR], 1.58) and antibiotic use (OR, 1.61). Increasing age was associated with lower odds of ESS revision (OR, 0.82). Compared with those who had undergone limited surgery, the highest odds of revision ESS were observed at three years for patients who had undergone extensive surgery at index (OR, 14.13). A higher cumulative dose of oral corticosteroid was seen in patients undergoing multiple ESS revisions (63 percent; median daily dose, 3.29 mg) versus patients without revisions (49 percent; median daily dose, 1.64 mg).
"The results indicate that severe chronic rhinosinusitis with nasal polyps is often associated with asthma," Toppila-Salmi said in a statement. "Patients with a severe form of the disease may benefit from additional treatments, such as biologics, if the disease cannot be managed despite repeated courses of antibiotics, oral corticosteroids, and sinus surgeries."
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, the study's sponsor.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
Perioperative Counseling Reduces Opioid Use After ACL Reconstruction Surgery
TUESDAY, July 29, 2025 -- Opioid-limiting pain management education and counseling reduce opioid consumption with no increase in postoperative pain among patients undergoing...
Risk-Reducing Mastectomy Cost-Effective With Breast Cancer Risk ≥35 Percent
MONDAY, July 28, 2025 -- Undergoing risk-reducing mastectomy (RRM) seems to be cost-effective for women aged 30 to 55 years with a lifetime breast cancer (BC) risk of 35 percent...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.